Literature DB >> 19172524

Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction.

Shariff Attaya1, Yogendra Kanthi, Richard Aster, Keith McCrae.   

Abstract

We present a case of eptifibatide-induced acute profound thrombocytopenia in a 64-year-old male receiving eptifibatide for the second time during percutaneous coronary intervention. Although rare, short and self-limited episodes of acute and profound thrombocytopenia have been associated with eptifibatide exposure. The thrombocytopenia is thought to be immune mediated, and assays are available to test for eptifibatide-induced platelet antibodies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19172524      PMCID： PMC4507797          DOI： 10.1080/09537100802592676

Source DB:  PubMed          Journal:  Platelets        ISSN： 0953-7104            Impact factor:   3.862


  14 in total

1.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

Review 2.  Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.

Authors:  Richard H Aster
Journal:  Chest       Date:  2005-02       Impact factor: 9.410

3.  Delayed profound thrombocytopenia associated with eptifibatide.

Authors:  Adedayo A Onitilo
Journal:  Am J Hematol       Date:  2006-12       Impact factor: 10.047

Review 4.  Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.

Authors:  Lindsay M Huxtable; Mohammad J Tafreshi; Amol N S Rakkar
Journal:  Am J Cardiol       Date:  2005-12-01       Impact factor: 2.778

Review 5.  Drug-induced immune thrombocytopenia.

Authors:  Richard H Aster; Daniel W Bougie
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

6.  Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.

Authors:  D C Sane; L V Damaraju; E J Topol; C F Cabot; M A Mascelli; R A Harrington; M L Simoons; R M Califf
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

7.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

9.  Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug.

Authors:  B R Curtis; A Divgi; M Garritty; R H Aster
Journal:  J Thromb Haemost       Date:  2004-06       Impact factor: 5.824

Review 10.  Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

Authors:  R H Aster; B R Curtis; D W Bougie; S Dunkley; A Greinacher; T E Warkentin; B H Chong
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824
View more
  3 in total

1.  A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.

Authors:  Payal C Desai; Julia E Brittain; Susan K Jones; Adam McDonald; Douglas R Wilson; Rosalie Dominik; Nigel S Key; Leslie V Parise; Kenneth I Ataga
Journal:  Thromb Res       Date:  2013-08-08       Impact factor: 3.944

2.  Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction.

Authors:  Michael Weinreich; Dexter Mendoza; Thomas Pettei; Evelina Grayver
Journal:  Cardiol Res       Date:  2014-12-04

3.  Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage.

Authors:  Gregory Byrd; Sabina Custovic; David Byrd; Deanna Ingrassia Miano; Jasdeep Bathla; Antonious Attallah
Journal:  Case Rep Crit Care       Date:  2021-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.